- New LOI would allow the company to join development of a wide range of hemp-based medicinal products
- Neutra would also gain access to a cultivation license and a research license to examine the role of cannabinoids as antioxidants and neuro-protectants
- CBD sales in the U.S. expected to exceed $20 billion by 2024; hemp-based CBD product sales reached $390 in 2018 and are expected to more than triple over the next couple of years
Early-stage research and development company Neutra Corp. (OTC: NTRR) executed a Letter of Intent (LOI) that could lead to the joint development of a vast selection of additional hemp-based medicinal products on the booming CBD market, according to a company press release (http://cnw.fm/hUH7u).
Neutra intends to conclude an agreement with Orgaceutical Co, based in Harrisburg, PA. If executed as planned, the agreement would provide Neutra with access to Orgaceutical’s formal research findings into the potential benefits of cannabinoids as antioxidants and neuro-protectants. Neutra, who is expanding into hemp cultivation and purified hemp extract products, would also gain a license for hemp cultivation issued by the Commonwealth of Pennsylvania’s Department of Agriculture as Orgaceutical Co is based in that state. The company would obtain rights to a federally registered hemp trademark as well.
According to Neutra CEO Sydney Jim, this agreement would help Neutra secure a solid position for research and development of new applications for hem-based CBD medicinal products. “With the cultivation license, we’ll have a constant and consistent supply of quality hemp under a vertically integrated cultivation model. With the research license, we’ll be free to explore new uses for hemp and products derived from it. Finally, with the trademark, we’ll have a federally protected brand name to pair with our existing VIVIS product line,” Jim said in a news release.
Neutra has been developing third-party certified hemp-derived CBD health and nutritional product lines for consumers for quite some time. The company recently acquired VIVIS, an emerging retail brand of hemp-based health and nutritional products. VIVIS has launched a soft gel CBD supplement, which was a crucial step in both its own and Neutra’s development as soft gel is the most efficient CBD ingestion method. This is because an entire dosage of CBD can be taken at once rather than spread out over time and lost to a great extent, as it would be when consumed in a beverage or a meal.
VIVIS’ hemp-derived CBD products are third-party certified as being of consistent quality and potency and free of contaminants. As global CBD markets become more strictly regulated, buyers are increasingly looking for certification when they buy these products. Neutra is expecting interest and demand for its expanding portfolio of branded products to increase with VIVIS as its new retail face.
Neutra recently signed a Letter of Intent to acquire J3 Holdings. This acquisition will include the latter’s land and warehouse as well as a license to cultivate hemp and refine it into usable forms. This approach will enable the company to grow its own hemp supply, giving it greater control over the selection of ingredients and allowing it to make sure they are of supreme quality.
The Orgaceutical LOI announcement came shortly after Neutra made the news earlier in October 2019 with its new CBD-based, menthol-infused sports cream, under the VIVIS brand (http://cnw.fm/lk4Zh). With one in five Americans participating in a sport or exercising regularly, and a growing global sports nutrition market, the company expects considerable interest in its new product.
These recent developments give Neutra quite an advantage on the rapidly expanding CBD product market. BDS Analytics and Arcview Market Research project that the collective market for CBD sales in the U.S. will exceed $20 billion by 2024, with a 49 percent compound annual growth rate across all distribution channels (http://cnw.fm/rneD4). However, Neutra’s interests go above and beyond sales. “Most of our focus, obviously, is in our quality and potency of our products, because there is a vast difference between very cheap products and quality product,” Jim said in an exclusive interview with NetworkNewsWire. It takes a lot of time to extract CBD and make sure only the best quality is made available (http://cnw.fm/VQ3mT).
Neutra’s vastly expanding horizons include the commercialization of more innovative and effective products. The company is always looking for new opportunities to accelerate its mission to bring these products to a wider demographic. Neutra’s work reflects a strong commitment to supporting better health, environment, and quality of life for people around the world.
For more information, visit the company’s website at www.NeutraInc.com
NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://cnw.fm/NTRR
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
